7 completed, 5 recruiting, 4 unknown, 3 active not recruiting. 15 Phase 2, 6 Phase 1, 4 Not applicable.
Follow Undifferentiated Pleomorphic Sarcoma: new trials by email Literature Review of Undifferentiated Pleomorphic Sarcoma trials Research Report on Undifferentiated Pleomorphic Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma Biopsy, Chest Computed Tomography, Chest Radiography - Adult Pleomorphic Rhabdomyosarcoma, AJCC Grade 2 Sarcoma | Not applicable | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 1582 | 2025-01-28 | 2024-07-30 |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas Osteosarcoma, Bone Tumor | Not yet recruiting | Klinikum Stuttgart | 1000 | 2022-09-01 | 2022-08-25 | |
| Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas Association of pembrolizumab + cabozantinib - Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma | Phase 2 | Recruiting | Institut Bergonié | 119 | 2022-04-25 | 2025-10-07 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients Propranolol, Pembrolizumab - Soft Tissue Sarcoma Adult, Angiosarcoma | Phase 2 | Recruiting | Niels Junker | 80 | 2021-08-17 | 2023-07-27 |
| ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Envafolimab, Ipilimumab - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 2 | Unknown | Tracon Pharmaceuticals Inc. | 207 | 2020-12-09 | 2024-05-17 |
| Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab - Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 14 | 2020-10-14 | 2026-03-10 |
| A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin - Sarcoma, Myxofibrosarcoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2020-04-01 | 2026-04-23 |
| Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas Treatment by Regorafenib, Surveillance - Bone Sarcoma, Osteosarcoma | Not applicable | Recruiting | Centre Leon Berard | 168 | 2020-03-03 | 2026-02-17 |
| Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS) - Undifferentiated Pleomorphic Sarcoma | Not applicable | Terminated | Matthew Bucknor | 5 | 2020-01-23 | 2026-06-01 |
| Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas DCC-3014, Avelumab - Sarcoma, Advanced Sarcoma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 32 | 2020-01-22 | 2025-08-28 |
| Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients Trabectedin - Soft Tissue Sarcoma Adult, Undifferentiated Pleomorphic Sarcoma | Not applicable | Completed | Institut Bergonié | 29 | 2020-01-06 | 2026-03-06 |
| Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Biopsy Procedure, Biospecimen Collection, Magnetic Resonance Imaging - Leiomyosarcoma, Liposarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2019-12-31 | 2026-11-12 |
| A Study of LY3435151 in Participants With Solid Tumors LY3435151, Pembrolizumab - Solid Tumor, Triple-negative Breast Cancer | Phase 1 | Terminated | Eli Lilly and Company | 2 | 2019-10-28 | 2021-08-31 |
| Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma Anlotinib, Toripalimab, Blood Draw - Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Unknown | Di Wu | 25 | 2019-07-19 | 2019-07-10 |
| A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Eribulin, Pembrolizumab - Sarcoma, Liposarcoma | Phase 2 | Completed | Dana-Farber Cancer Institute | 57 | 2019-06-04 | 2025-08-28 |
| A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) XmAb®23104, Yervoy® (ipilimumab) - Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma | Phase 1 | Completed | Xencor, Inc. | 198 | 2019-05-01 | 2024-07-05 |
| Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Hypofractionated radiotherapy, Hyperthermia - Sarcoma, Alveolar Soft Part Sarcoma | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 30 | 2018-06-01 | 2021-02-01 |
Showing 20 of 25. Sign in to see all of them.
Histiocytoma, Malignant Fibrous (25) · Sarcoma (19) · Leiomyosarcoma (13) · Liposarcoma (11) · Dermatofibrosarcoma (10) · Sarcoma, Synovial (9) · Hemangiosarcoma (7) · Neurofibrosarcoma (6) · Fibrosarcoma (5) · Bone Neoplasms (4) · Osteosarcoma (4) · Sarcoma, Alveolar Soft Part (3) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Hepatocellular (2) · Liposarcoma, Myxoid (2)
Histiocytoma (25) · Neoplasms by Histologic Type (25) · Neoplasms, Connective Tissue (25) · Neoplasms, Connective and Soft Tissue (25) · Neoplasms, Fibrous Tissue (25) · Neoplasms (23) · Neoplasms, Muscle Tissue (14) · Neoplasms, Adipose Tissue (11) · Neoplasms, Vascular Tissue (8) · Fibrosarcoma (7) · Neoplasms by Site (7) · Neoplasms, Nerve Tissue (7) · Nerve Sheath Neoplasms (6) · Nervous System Diseases (6) · Nervous System Neoplasms (6)
pembrolizumab (4) · Ipilimumab (3) · Radiation (3) · Radiotherapy (3) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Biopsy (2) · Docetaxel (2) · Doxorubicin (2) · Gemcitabine (2) · Nivolumab (2) · Radiation Dose Hypofractionation (2) · BO-112 (1) · Biopsy, Needle (1) · Blood Specimen Collection (1) · CTLA-4 Antigen (1)
Brown University (2) · Institut Bergonié (2) · Maria Sklodowska-Curie National Research Institute of Oncology (2) · Memorial Sloan Kettering Cancer Center (2) · AbbVie (1) · BioAtla, Inc. (1) · Centre Leon Berard (1) · Dana-Farber Cancer Institute (1) · Di Wu (1) · ECOG-ACRIN Cancer Research Group (1) · Eli Lilly and Company (1) · HRYZ Biotech Co. (1) · Jonsson Comprehensive Cancer Center (1) · Klinikum Stuttgart (1) · M.D. Anderson Cancer Center (1)
United States (15) · France (4) · China (2) · Poland (2) · Canada (1) · Denmark (1) · Hong Kong (1) · Japan (1) · Norway (1) · Spain (1) · Sweden (1) · Taiwan (1) · United Kingdom (1)
Bradley D DeNardo, MD (1) · Bradley DeNardo, MD (1) · Brian A Van Tine, M.D., Ph.D. (1) · Charles Theuer, MD, PhD (1) · Chet Bohac, MD, MSc (1) · Christina L Roland (1) · Don S Dizon, MD (1) · Edmund Bartlett, MD (1) · Galina G Lagos, MD (1) · Kenneth Cardona (1)
PMID 30249211, PMID 34722269, PMID 35115306, PMID 35260879, PMID 38236580, PMID 38579194, PMID 42194972
2015 (1), K08CA245181 (1), UG1CA189828 (1), UM1CA186686 (1), UM1CA186709 (1)